查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984180

新抗原癌症疫苗市场：依新抗原类型、治疗标靶、疫苗平台、给药途径和最终用户划分－2026-2032年全球市场预测

Neoantigen Cancer Vaccine Market by Neoantigen Type, Therapeutic Target, Vaccine Platform, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，新抗原癌症疫苗市场价值将达到 175.1 亿美元，到 2026 年将成长至 196.5 亿美元，到 2032 年将达到 415.8 亿美元，复合年增长率为 13.15%。

主要市场统计数据
基准年 2025 175.1亿美元
预计年份：2026年 196.5亿美元
预测年份 2032 415.8亿美元
复合年增长率 (%) 13.15%

对新抗原癌症疫苗进行简明介绍，整合科学创新、临床进展和相关人员的策略考量。

新抗原癌症疫苗代表了肿瘤学领域的模式转移，它利用肿瘤特异性肽段特征诱导针对恶性肿瘤的适应性免疫。这些治疗方法的核心在于利用肿瘤特异性突变或復发性肿瘤相关改变产生的独特或通用新抗原（抗原决定簇）精确诱导T细胞反应。定序、生物资讯学和合成生物学的进步缩短了从发现到生产的周期，使得从肿瘤切片检查到候选疫苗的快速转化成为可能。这种技术融合已将新抗原疫苗从概念性的可能性转变为涵盖学术机构、生物技术公司和临床联盟的强大转化流程。

对技术、临床、製造和监管领域的变革性变化进行分析概述，重新定义新抗原疫苗向下一代创新发展的前景。

新抗原疫苗领域正经历一场变革，这场变革由四个相互关联的因素驱动：技术成熟度、联合治疗的临床检验、不断发展的供应链以及不断变化的监管预期。技术成熟度包括肿瘤定序处理能力的提升、表位预测演算法的改进以及能够提高抗原表达保真度的新一代RNA和DNA递送平台。这些进步消除了候选疫苗筛选的瓶颈，并使得设计更具免疫抗原性的构建体成为可能。因此，研发人员正在探索诸如环状DNA支架和新一代RNA化学等创新平台，以加速疫苗的优化，并提高其稳定性和免疫启动能力。

对计划于 2025 年进行的美国关税调整将如何影响整个新抗原疫苗生态系统的供应链选择、製造地和筹资策略进行现实评估。

美国正在实施或计划于2025年实施的关税政策对新抗原疫苗研发企业的商业决策产生了重大影响。尤其值得注意的是，该领域依赖全球分散的试剂、合成寡核苷酸、脂质奈米颗粒、特殊耗材和生物製程设备等供应基地。提高进口试剂和组件的关税可能会增加原料的取得成本，这可能会挤压早期研发企业（尤其是那些采购量较小的企业）的利润空间。为此，许多机构正在调整筹资策略，优先选择国内或区域供应商，重新与供应商谈判合同，并加快对替代来源的认证，以确保关键原材料供应的持续性。

透过整合新抗原类型、治疗标靶、疫苗平台、给药途径和最终用户等因素，进行全面的细分洞察，从而指导策略优先排序。

市场区隔为评估新抗原疫苗的临床应用、技术选择和商业化路径提供了一个实用的架构。根据新抗原的类型，市场被划分为「个人化新抗原」和「通用新抗原」共用类。 「个人化新抗原」透过免疫逃脱突变和体细胞突变进行更深入的研究，而「共用新抗原」则着重于亲和性和胜肽和常见肿瘤突变进行评估。这种细分有助于明确治疗范围。个人化策略优先考虑根据个别突变谱定制的抗原库，而共用策略则针对复发性突变，以实现更广泛的患者应用并提供现成产品。

美洲、欧洲、中东和非洲以及亚太地区新抗原疫苗开发的关键区域趋势和操作考虑因素。

区域趋势对新抗原疫苗计画的研发强度、监管环境、生产策略和市场进入有显着影响。在美洲，丰富的创新环境、广泛的临床试验网络和雄厚的私人资本支持技术的快速实用化；然而，复杂的支付方环境和临床实验中心的推出等后勤物流可能会影响专案进度。美国尤其如此，它仍然是平台创新和首次人体试验的中心，其遍布北美的网路促进了多中心试验和公私合营。

对新抗原疫苗商业化过程中的平台领导者、合作模式和智慧财产权趋势进行策略竞争格局分析。

新抗原疫苗领域呈现出多元化的格局，既有专注于个人化治疗的先锋生物技术公司，也有将新抗原平台整合到更广泛的肿瘤免疫产品组合中的领先肿瘤公司。主要企业致力于提昇平台的稳健性（抗原预测的准确性、生产速度和抗原呈现的广度），而策略伙伴则负责扩大生产规模、分销管道以及后期临床开发。学术研究机构仍然是转化创新的重要来源，它们进行早期临床试验，以检验抗原选择方法和联合治疗。

为产业领导者提供切实可行的建议，以协调平台创新、监管合作和供应链韧性，从而确保新抗原疫苗计画的成功。

产业领导者应采取多管齐下的策略，将科学差异化、营运韧性和市场准入计画结合。首先，应优先投资于能够缩短从肿瘤定序到疫苗上市时间的平台，这些平台应整合先进的预测演算法、自动化生产流程和可靠的品管检测方法。同时，应建立灵活的生产伙伴关係和区域供应链，以降低关税风险并确保关键原材料的持续供应。

一种透明且可重复的调查方法，它结合了与专家的初步访谈、严格的二次分析和结构化的技术评估框架。

本研究整合了对临床研究人员、监管专家、生产负责人和商业负责人的访谈，以及对同行评审文献、临床试验註册资料和公开监管指南的二次分析。资料收集过程中註重可重复性。具体而言，访谈通讯协定经过标准化，以了解专案设计选择、营运挑战和策略重点，并将定性回答与已记录的案例研究和监管申报文件进行交叉核对，以确保准确性。

具有前瞻性的结论，融合了科学进步、运作挑战和协作方法，以促进新抗原疫苗的广泛应用。

新抗原癌症疫苗正处于一个转折点，科学的成熟与营运创新相融合，开启了新的治疗可能性。抗原预测技术的改进、多样化的递送平台以及策略性临床联合治疗的整合，正在建立一条从药物发现到患者应用的可行路径。同时，供应链脆弱性、监管协调以及可扩展生产的需求等实际挑战，需要谨慎的策略应对，才能将免疫学潜力转化为广泛可及的疗法。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：新抗原癌症疫苗市场（以新抗原类型划分）

  • 个人化新抗原
    • 免疫逃脱突变
    • 体细胞突变
  • 共用的新抗原
    • 亲和性肽
    • 通用肿瘤突变

第九章：按治疗标靶分類的新抗原癌症疫苗市场

  • 免疫查核点抑制
    • CTLA-4抑制剂
    • PD-1抑制剂
  • 肿瘤新抗原
    • 突变新抗原
    • 非突变新抗原

第十章：以疫苗平台分類的新抗原癌症疫苗市场

  • 细胞疫苗
    • 树突细胞疫苗
    • T细胞疫苗
  • DNA疫苗
    • 环状DNA平台
    • 质体DNA疫苗
  • 基于胜肽的疫苗
    • 长链胜肽
    • 合成胜肽
  • 基于RNA的疫苗
    • 药效疫苗
    • 下一代RNA平台

第十一章 新抗原癌症疫苗市场（依给药途径划分）

  • 皮内注射
  • 静脉
  • 口服
  • 皮下

第十二章：新抗原癌症疫苗市场：依最终用户划分

  • 癌症治疗中心
  • 医院
  • 研究机构

第十三章：新抗原癌症疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 新抗原癌症疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：新抗原癌症疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国新抗原癌症疫苗市场

第十七章：中国新抗原癌症疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agenus Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Ayala Pharmaceuticals, Inc.
  • BioLineRx Ltd.
  • BioNTech SE
  • BioVaxys Technology Corp.
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac NV
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Genocea Biosciences Inc
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neophore Limited
  • Nouscom AG
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis Srl
Product Code: MRR-5C6F41F5AFED

The Neoantigen Cancer Vaccine Market was valued at USD 17.51 billion in 2025 and is projected to grow to USD 19.65 billion in 2026, with a CAGR of 13.15%, reaching USD 41.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.51 billion
Estimated Year [2026] USD 19.65 billion
Forecast Year [2032] USD 41.58 billion
CAGR (%) 13.15%

A concise introduction to neoantigen cancer vaccines that synthesizes scientific innovation, clinical momentum, and strategic considerations for stakeholders

Neoantigen cancer vaccines represent a paradigm shift in oncology, harnessing tumor-specific peptide signatures to mobilize adaptive immunity against malignancies. At their core, these interventions exploit unique or shared neoantigens-antigenic determinants arising from tumor-specific mutations or recurrent tumor-associated changes-to direct T cell responses with precision. Advances in sequencing, bioinformatics, and synthetic biology have compressed the discovery-to-manufacture timeline, enabling more rapid translation from tumor biopsy to vaccine candidate. This technical convergence has moved neoantigen vaccines from conceptual promise to a robust translational pipeline across academic centers, biotechnology companies, and clinical consortia.

Clinically, neoantigen strategies are being evaluated across monotherapy settings and in combination with established modalities such as immune checkpoint inhibitors and adoptive cell therapies. The evidence base emphasizes immunogenicity, safety, and the capacity to broaden antitumor T cell repertoires. Operationally, the space demands interdisciplinary coordination-genomics, antigen prediction, GMP manufacturing, and clinical operations-creating both opportunities and complexity for developers and their partners. Consequently, strategic clarity around segmentation, regional dynamics, supply chain resilience, and commercialization pathways has become essential for stakeholders aiming to convert scientific advances into durable clinical and commercial outcomes.

An analytical synthesis of the transformative technological, clinical, manufacturing, and regulatory shifts redefining the neoantigen vaccine landscape for the next wave of innovation

The neoantigen vaccine landscape is undergoing transformative shifts driven by four interlocking forces: technological maturation, clinical validation of combination approaches, supply chain evolution, and shifting regulatory expectations. Technological maturation spans improvements in tumor sequencing throughput, enhanced algorithms for epitope prediction, and next-generation RNA and DNA delivery platforms that increase antigen expression fidelity. These advances have reduced bottlenecks in candidate identification while enabling the design of more immunogenic constructs. As a result, developers are iterating faster and exploring innovative platforms such as circular DNA scaffolds and next-gen RNA chemistries to improve stability and immune priming.

Clinically, emerging data from studies that pair neoantigen vaccines with immune checkpoint blockade have catalyzed a move from purely experimental protocols to structured combinatorial strategies with clearer endpoints. This clinical momentum is accompanied by changes in manufacturing paradigms; decentralized and regionalized production models are being piloted to shorten turnaround times and address cold chain dependencies. Regulatory frameworks are also adapting, with agencies increasingly open to streamlined pathways for individualized biologics while emphasizing standardized potency assays and robust pharmacovigilance. Together, these shifts are redefining how programs are designed, financed, and brought to patients, emphasizing modular, scalable approaches and strategic partnerships across the ecosystem.

A pragmatic assessment of how United States tariff adjustments slated for 2025 are shaping supply chain choices, manufacturing footprints, and procurement strategies across the neoantigen vaccine ecosystem

Tariff policies implemented or anticipated by the United States for 2025 have had a material influence on the operational calculus of neoantigen vaccine developers, particularly because the sector relies on an internationally distributed supply base for reagents, synthetic oligonucleotides, lipid nanoparticles, specialized consumables, and bioprocess equipment. Increased duties on imported reagents and components raise the landed cost of inputs and can compress margins for early-stage developers who lack purchasing scale. In response, many organizations have adjusted procurement strategies to prioritize domestic or regional suppliers, renegotiated supplier contracts, and accelerated qualification of alternative sources to maintain continuity of critical raw materials.

Beyond unit cost implications, cumulative tariff effects have reinforced the strategic rationale for nearshoring and regional manufacturing. Developers and contract manufacturers are increasingly evaluating the trade-offs between capitalizing on lower-cost offshore production and accepting longer lead times and tariff exposure. At the same time, tariffs have prompted greater attention to supply chain transparency, inventory planning, and dual-sourcing to mitigate single-source risk. On the policy front, developers are engaging more actively with trade associations and regulators to clarify tariff classifications for biologics and associated materials, seeking exemptions or tariff relief when feasible. Collectively, these adjustments are shaping decision-making around facility investment, partnership selection, and program timelines without altering the fundamental scientific trajectories of neoantigen vaccine development.

Comprehensive segmentation insights that integrate neoantigen types, therapeutic targets, vaccine platforms, administration routes, and end users to guide strategic prioritization

Segmentation offers a pragmatic framework to evaluate clinical applications, technology choices, and commercialization pathways for neoantigen vaccines. Based on neoantigen type, the market is studied across Personalized Neoantigens and Shared Neoantigens; Personalized Neoantigens are further examined through immune escape mutations and somatic mutations, while Shared Neoantigens are assessed with attention to affinity peptides and common tumor mutations. This segmentation clarifies therapeutic scope: personalized approaches prioritize bespoke antigen repertoires tailored to an individual's mutational landscape, whereas shared strategies target recurrent alterations that enable broader patient applicability and potential off-the-shelf offerings.

Based on therapeutic target, the market is studied across Immune Checkpoint Blockade and Tumor Neoantigens; Immune Checkpoint Blockade is further examined across CTLA-4 inhibitors and PD-1 inhibitors, and Tumor Neoantigens are further parsed into mutated neoantigens and non-mutated neoantigens. This axis highlights the importance of combinatorial design and target selection in optimizing immune activation. Based on vaccine platform, the market is studied across Cell-Based Vaccines, DNA-Based Vaccines, Peptide-Based Vaccines, and RNA-Based Vaccines; Cell-Based Vaccines are further examined across dendritic cell vaccines and T-cell vaccines, DNA-Based Vaccines are further explored across circular DNA platforms and plasmid DNA vaccines, Peptide-Based Vaccines are further categorized into long peptides and synthetic peptides, and RNA-Based Vaccines are further evaluated across mRNA vaccines and next-generation RNA platforms. This platform segmentation illuminates trade-offs in manufacturing complexity, antigen expression durability, and dosing strategies. Based on administration route, the market is studied across intradermal, intravenous, oral, and subcutaneous delivery, an axis that affects immunogenicity, patient experience, and clinical logistics. Finally, based on end user, the market is studied across cancer treatment centers, hospitals, and research institutes, underscoring where clinical adoption, trial execution, and translational research investment are concentrated. Together, these segmentation lenses enable strategic prioritization of clinical indications, platform investments, and partner selection to maximize translational and commercial impact.

Key regional dynamics and operational considerations for neoantigen vaccine development across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exert a strong influence on R&D intensity, regulatory timelines, manufacturing strategy, and commercial access for neoantigen vaccine programs. In the Americas, an innovation-rich environment with extensive clinical trial networks and significant private capital supports rapid technology translation, though program timelines can be affected by complex payer landscapes and site activation logistics. The United States in particular remains a center for platform innovation and first-in-human studies, while broader North American networks facilitate multi-center studies and public-private collaborations.

In Europe, Middle East & Africa, diverse regulatory jurisdictions and a strong foundation in academic translational research create opportunities for collaborative consortia and harmonized clinical evaluation through centralized regulatory mechanisms. Several countries within the region are advancing clinical infrastructure and adaptive trial frameworks conducive to personalized biologics. Asia-Pacific presents a heterogeneous landscape characterized by fast-growing biotech clusters, government-led incentives for biomanufacturing, and rapidly expanding clinical trial capacity. Emerging markets in the region are increasingly investing in local manufacturing capabilities and regulatory modernization, which can accelerate regional access but also necessitate tailored regulatory and commercialization strategies. Developers must therefore adopt a region-specific approach to partnerships, clinical site selection, and manufacturing footprint planning to align with differing regulatory expectations, reimbursement environments, and patient access pathways.

Strategic competitive landscape analysis highlighting platform leaders, partnership models, and intellectual property dynamics shaping neoantigen vaccine commercialization

The competitive landscape for neoantigen vaccines features a spectrum of organizations, from pioneering biotechs focusing on individualized approaches to larger oncology companies integrating neoantigen platforms into broader immuno-oncology portfolios. Leading developers concentrate on platform robustness-accuracy of antigen prediction, speed of manufacturing, and breadth of antigen presentation-while strategic collaborators provide scale in production, distribution, and late-stage clinical development. Academic centers remain crucial sources of translational innovation, hosting early trials that validate antigen selection methods and combination regimens.

Partnership models are evolving: strategic alliances with contract development and manufacturing organizations accelerate GMP translation; licensing deals with platform owners enable larger firms to access specialized antigen-prediction algorithms; and collaborative networks with clinical consortia expedite multicenter studies. Investment patterns prioritize platforms that can reduce time from sequence to product, support modular manufacturing, and de-risk regulatory pathways through standardized assay development. Intellectual property around epitope selection algorithms, delivery chemistry, and manufacturing processes is a differentiator, influencing strategic positioning and M&A interest as stakeholders seek to integrate vertical capabilities and shorten commercialization timelines.

Actionable recommendations for industry leaders to align platform innovation, regulatory engagement, and supply chain resilience for successful neoantigen vaccine programs

Industry leaders should adopt a multi-pronged strategy that aligns scientific differentiation with operational resilience and market access planning. First, prioritize platform investments that reduce turnaround time from tumor sequencing to vaccine release by integrating advanced prediction algorithms, automated manufacturing workflows, and robust quality control assays. Concurrently, establish flexible manufacturing partnerships and regional supply relationships to mitigate tariff exposures and ensure continuity of critical inputs.

Second, design clinical programs that emphasize strategic combinations with immune checkpoint inhibitors and standardized endpoints that resonate with regulators and payers. Early engagement with regulatory authorities to align on potency assays, safety monitoring frameworks, and evidence-generation plans will streamline later-stage development. Third, pursue modular commercialization strategies that balance personalized and shared neoantigen approaches; leverage shared neoantigen candidates to create scalable offerings while using personalized programs to address high-unmet-need indications. Finally, invest in cross-functional capabilities-data management, regulatory science, and health economics-to articulate value to payers, accelerate reimbursement discussions, and support sustainable adoption pathways.

A transparent and reproducible research methodology integrating primary expert interviews, rigorous secondary analysis, and structured technology assessment frameworks

This research synthesizes primary interviews with clinical investigators, regulatory experts, manufacturing leaders, and commercial strategists, alongside secondary analysis of peer-reviewed literature, clinical trial registries, and public regulatory guidance. Data collection emphasized reproducible methods: interview protocols were standardized to capture program design choices, operational challenges, and strategic priorities, and qualitative responses were triangulated with documented case studies and regulatory filings to ensure accuracy.

Analytical methods combined thematic analysis of qualitative inputs with technology assessment frameworks to evaluate platform readiness, manufacturability, and scalability. Risk assessments focused on supply chain dependencies, regulatory heterogeneity, and clinical development complexity. Comparative profiling of platforms and programs used consistent criteria-development stage, platform maturity, manufacturing complexity, and strategic partnerships-to support clear, comparable insights. Throughout, the methodology prioritized transparency and traceability so that conclusions can be validated against primary sources and updated as new data emerge.

A forward-looking conclusion that synthesizes scientific progress, operational imperatives, and collaborative pathways to advance neoantigen vaccine adoption

Neoantigen cancer vaccines are at an inflection point where scientific maturation and operational innovation are jointly unlocking new therapeutic possibilities. The convergence of improved antigen prediction, diversified delivery platforms, and strategic clinical combinations is creating viable pathways from discovery to patient administration. At the same time, practical challenges-supply chain exposures, regulatory harmonization, and the need for scalable manufacturing-require deliberate strategic responses to translate immunological promise into broadly accessible treatments.

Looking forward, success will favor organizations that combine scientific differentiation with operational discipline: those that can validate antigen selection empirically, demonstrate consistent manufacturing quality, and articulate economic value to payers. Collaborative ecosystems-linking developers, CDMOs, clinical networks, and regulators-will accelerate progress, while region-specific manufacturing and regulatory strategies will shape access. In sum, the field presents compelling opportunities for stakeholders who can integrate translational science with pragmatic execution to bring next-generation neoantigen vaccines into clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 8.1. Personalized Neoantigens
    • 8.1.1. Immune Escape Mutations
    • 8.1.2. Somatic Mutations
  • 8.2. Shared Neoantigens
    • 8.2.1. Affinity Peptides
    • 8.2.2. Common Tumor Mutations

9. Neoantigen Cancer Vaccine Market, by Therapeutic Target

  • 9.1. Immune Checkpoint Blockade
    • 9.1.1. CTLA-4 Inhibitors
    • 9.1.2. PD-1 Inhibitors
  • 9.2. Tumor Neoantigens
    • 9.2.1. Mutated Neoantigens
    • 9.2.2. Non-Mutated Neoantigens

10. Neoantigen Cancer Vaccine Market, by Vaccine Platform

  • 10.1. Cell-Based Vaccines
    • 10.1.1. Dendritic Cell Vaccines
    • 10.1.2. T-Cell Vaccines
  • 10.2. DNA-Based Vaccines
    • 10.2.1. Circular DNA Platforms
    • 10.2.2. Plasmid DNA Vaccines
  • 10.3. Peptide-Based Vaccines
    • 10.3.1. Long Peptides
    • 10.3.2. Synthetic Peptides
  • 10.4. RNA-Based Vaccines
    • 10.4.1. mRNA Vaccines
    • 10.4.2. Next-Gen RNA Platforms

11. Neoantigen Cancer Vaccine Market, by Administration Route

  • 11.1. Intradermal
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Subcutaneous

12. Neoantigen Cancer Vaccine Market, by End User

  • 12.1. Cancer Treatment Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Neoantigen Cancer Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neoantigen Cancer Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neoantigen Cancer Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neoantigen Cancer Vaccine Market

17. China Neoantigen Cancer Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agenus Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Avidea Technologies
  • 18.8. Ayala Pharmaceuticals, Inc.
  • 18.9. BioLineRx Ltd.
  • 18.10. BioNTech SE
  • 18.11. BioVaxys Technology Corp.
  • 18.12. Brightpath Biotherapeutics Co., Ltd.
  • 18.13. CureVac N.V.
  • 18.14. Elicio Therapeutics Inc
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • 18.17. Genocea Biosciences Inc
  • 18.18. GenScript Biotech Corporation
  • 18.19. Gilead Sciences, Inc.
  • 18.20. Gritstone bio, Inc.
  • 18.21. Immunomic Therapeutics, Inc.
  • 18.22. ISA Pharmaceuticals B.V.
  • 18.23. Medigene AG
  • 18.24. Merck & Co., Inc.
  • 18.25. Moderna, Inc.
  • 18.26. Neophore Limited
  • 18.27. Nouscom AG
  • 18.28. Nykode Therapeutics ASA
  • 18.29. OSE Immunotherapeutics
  • 18.30. Takis S.r.l.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 287. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 300. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 301. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO NEOANTIGEN CANCER